WebJul 1, 2024 · More recently, the combination of ipilimumab and nivolumab (Ipi/Nivo) gained approval as first-line therapy in RCC with better outcomes than previously described with Nivo. Whether Ipi/Nivo can rescue RCC patients who progress on Nivo is an important question that remains unanswered. We sought to evaluate the oncologic benefit of … WebAug 3, 2024 · On July 10, the Food and Drug Administration (FDA) approved the combination of two immunotherapy drugs— ipilimumab (Yervoy) and nivolumab (Opdivo) —for the treatment of some patients with metastatic colorectal cancer who have been treated previously with standard chemotherapy drugs.
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung
WebJun 10, 2024 · Study IPI-549-02 is a multi-national, prospective, randomized, active-control … Web1 day ago · The study investigated the immune-oncology (IO) and tyrosine kinase inhibitor (TKI) combination of nivolumab (Opdivo) and ipilimumab (Yervoy) or ipi/nivo plus cabozantinib (Cabometyx) vs ipi/nivo alone, and it showed positive results. The use of doublet IO/TKI therapy, however, can be rationalized. burned with desire
Rechallenge with checkpoint inhibitors in metastatic melanoma
WebApr 2, 2024 · There may be a role for triplet therapies in patients for whom IPI + NIVO is contraindicated or undesirable given the high rates of grades 3–4 immune-mediated toxicity associated with IPI + NIVO. Whilst the toxicity of triplet therapy is not insubstantial, the profile is arguably more tolerable than that of IPI + NIVO, with the exception of ... http://aimwithimmunotherapy.org/wp-content/uploads/2024/07/IPI-Nivo-Lung-Toolkit-2024.pdf WebMar 16, 2024 · The primary hypothesis to be tested was that, in patients with NSCLC amenable for surgical resection, induction therapy with Nivo+CT or Ipi+Nivo+CT will produce MPR rates of at least 40%, a target ... halzl aircraft